Analysts on Wall Street project that MetLife (MET) will announce quarterly earnings of $2.30 per share in its forthcoming report, representing an increase of 13.9% year over year. Revenues are projected to reach $19.34 billion, increasing 7.9% from the same quarter last year.
Over the last 30 days, there has been a downward revision of 0.3% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some MetLife metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts forecast 'Revenue- Other Revenues' to reach $742.31 million. The estimate suggests a change of +9.3% year over year.
The combined assessment of analysts suggests that 'Revenue- Net investment income' will likely reach $5.50 billion. The estimate suggests a change of -2.8% year over year.
The consensus among analysts is that 'Revenue- Universal life and investment-type product policy fees' will reach $1.32 billion. The estimate points to a change of +4.7% from the year-ago quarter.
According to the collective judgment of analysts, 'Revenue- Premiums' should come in at $11.97 billion. The estimate suggests a change of +10.7% year over year.
Analysts predict that the 'Total Adjusted Revenue- Latin America' will reach $2.25 billion. The estimate suggests a change of +8.5% year over year.
Analysts' assessment points toward 'Adjusted Revenue- Corporate & other- Net investment income' reaching $974.37 million. The estimate indicates a year-over-year change of +1354.3%.
The consensus estimate for 'Total Adjusted Revenue- EMEA' stands at $846.38 million. The estimate indicates a year-over-year change of +8.5%.
The collective assessment of analysts points to an estimated 'Total Adjusted Revenue- Asia' of $3.11 billion. The estimate points to a change of +7% from the year-ago quarter.
It is projected by analysts that the 'Adjusted Revenue- Asia- Net investment income' will reach $1.39 billion. The estimate indicates a year-over-year change of +14.6%.
Based on the collective assessment of analysts, 'Adjusted Revenue- EMEA- Net investment income' should arrive at $67.41 million. The estimate suggests a change of +10.5% year over year.
Analysts expect 'Adjusted Revenue- Latin America- Net investment income' to come in at $440.74 million. The estimate indicates a change of -1% from the prior-year quarter.
The average prediction of analysts places 'Adjusted Revenue- Asia- Other Revenues' at $17.76 million. The estimate points to a change of -19.3% from the year-ago quarter.
Over the past month, shares of MetLife have returned +7.8% versus the Zacks S&P 500 composite's -0.5% change. Currently, MET carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Keep it Clean. Please avoid obscene, vulgar, lewd,
racist or sexually-oriented language. PLEASE TURN OFF YOUR CAPS LOCK. Don't Threaten. Threats of harming another
person will not be tolerated. Be Truthful. Don't knowingly lie about anyone
or anything. Be Nice. No racism, sexism or any sort of -ism
that is degrading to another person. Be Proactive. Use the 'Report' link on
each comment to let us know of abusive posts. Share with Us. We'd love to hear eyewitness
accounts, the history behind an article.
(0) comments
Welcome to the discussion.
Log In
Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.